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A conserved enhancer regulates Il9 expression in
multiple lineages
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Sarath Chandra Janga3 & Mark H. Kaplan1,2
Cytokine genes are regulated by multiple regulatory elements that confer tissue-speciﬁc and
activation-dependent expression. The cis-regulatory elements of the gene encoding IL-9, a
cytokine that promotes allergy, autoimmune inﬂammation and tumor immunity, have not
been deﬁned. Here we identify an enhancer (CNS-25) upstream of the Il9 gene that binds
most transcription factors (TFs) that promote Il9 gene expression. Deletion of the enhancer
in the mouse germline alters transcription factor binding to the remaining Il9 regulatory
elements, and results in diminished IL-9 production in multiple cell types including Th9 cells,
and attenuates IL-9-dependent immune responses. Moreover, deletion of the homologous
enhancer (CNS-18) in primary human Th9 cultures results in signiﬁcant decrease of IL-9
production. Thus, Il9 CNS-25/IL9 CNS-18 is a critical and conserved regulatory element for
IL-9 production.
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Gene transcription occurs through a concerted network oftransacting factors and cis-acting DNA regulatory ele-ments. Apart from gene promoters, directly adjacent to
the transcriptional start site (TSS), enhancers exist at more distant
sites from the TSS and can be both 5′ and 3′ of the gene locus1,2.
Enhancers not only facilitate transcription but can confer tissue-
and cell-type-speciﬁc expression.
In T cells, there are multiple examples of enhancer-speciﬁed
gene regulation. Among the best characterized are cytokine genes,
particularly the Ifng and Il4-Il13 cytokine loci where multiple
enhancers and locus control regions have been identiﬁed3–6.
Several of these elements, many based on conserved non-coding
sequences (CNSs) or measures of open chromatin such as DNase
Hypersensitivity assays, have been deleted in mouse models and
have demonstrated function in vitro and in vivo7–13. These stu-
dies have improved our understanding of how lineage-speciﬁc
genes are regulated, and how precise gene regulation contributes
to immune responses.
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Fig. 1 Identiﬁcation of a CNS-25 p300-binding element in the Il9 gene. Naive CD4+ T cells were isolated from C57BL/6 mice and cultured under the
indicated Th cell polarizing conditions. On day 5, cells were harvested for ChIP analysis using p300 antibody. a ChIP-seq analysis of p300 in Th9 cells at
the Il9 locus and comparison with ChIP-seq analysis of p300, H3K4me1, and STAT6 in Th2 cells (GSE22104 and GSE40463). Bottom, putative
transcription factor-binding motifs in the most conserved regions of CNS-25. b Venn diagram indicating the overlap in Th9-enriched genes and p300-
binding peaks in Th9 cells. c ChIP assay analysis of p300 at the CNS regions of the Il9 locus in Th cell subsets. Non-conserved sequences −12 and −35 kb
were used as negative controls. Percent input depicted are the p300 ChIP values after subtraction of the control IgG ChIP values. d p300 and IgG ChIP
values at the CNS-25 in Th9 cells. e p300 inhibitor added to Th9 cell cultures on day 3. On day 5, cells were harvested and restimulated with anti-CD3
overnight to assess IL-9 production using ELISA. Data are represented as mean ± SEM from three independent experiments (n= 3 or 4 per group). c One-
way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. **p < 0.01, ***p < 0.001. e A two-tailed Student’s t test
was used for pairwise comparisons. **p < 0.01
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Interleukin (IL)-9 is a pleiotropic cytokine that impacts many
cells and is involved in diverse immune responses14,15. IL-9, and
the cells that produce it, are linked to tumor immunity, immunity
to pathogens, allergy, and autoimmune disease. Major producers
of IL-9 include T helper (Th) 9 cells and type 2 innate lymphoid
cells (ILCs), although mast cells (MCs) and basophils produce
IL-9, and other Th subsets may express limited amounts of IL-9
in some conditions. Despite a growing understanding of the role
of IL-9 in immunity and disease, transcriptional regulation of the
Il9 gene is still not well understood. In Th9 cells, the best studied
IL-9-secreting cell, expression of IL-9 relies upon a network of
transcription factors that include Smad proteins, STAT5, STAT6,
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Forkhead box family members, PU.1, BATF, and interferon
regulatory factor 4 (IRF4)16–27. These trans-factors bind to, and
mediate chromatin modiﬁcations at, the Il9 promoter (Il9p or
CNS1) and at two other potential regulatory elements, termed
CNS2/CNS+ 5.5 and CNS0/CNS-6, that are respectively 5.5 kb
downstream and 6 kb upstream of the Il9 TSS16,28. OX40-induced
super-enhancers of the Il9 gene have been identiﬁed, and a super-
enhancer overlapping CNS+ 5.5 was critical for OX40-induced
IL-9 production, though it was not clear if this element is
important for OX40-indendent IL-9 production29. Although
most IL-9-promoting transcription factors bind at the Il9p17,30,31,
it is still possible that there are additional unidentiﬁed regulatory
elements of Il9 expression.
Here we use a combination of bioinformatics and experimental
approaches to deﬁne an Il9 enhancer element that regulates IL-9
production within multiple cell lineages. We show that an ele-
ment 25 kb upstream from the Il9 gene (termed Il9 CNS-25) has
enhancer characteristics deﬁned by histone modiﬁcations, tran-
scription factor binding, and reporter assays. Importantly, mice
lacking the CNS-25 element (Il9ΔCNS-25 mice) have T cells, MCs,
and basophils that produce signiﬁcantly less IL-9 than wild-type
(WT) mice in vitro and in vivo. Deletion of the homologous
element in primary human Th9 cells also results in less IL-9
production. Thus, we conclude that Il9 CNS-25 is a critical
conserved enhancer for Il9 gene expression and will provide an
entry point for further understanding the regulation of this
immunoregulatory cytokine.
Results
Identiﬁcation of Il9 CNS-25. To begin to deﬁne additional
regulatory elements of the Il9 gene, we performed chromatin
immunoprecipitation and high-throughput sequencing (ChIP-
seq) analysis of Th9 cells using Abs to the transcriptional co-
activator p300, which is documented to be associated with
enhancer elements32,33. Analysis identiﬁed 2973 p300 occupancy
peaks, including within the Il9 gene, that were predominantly
localized to protein-coding genes but spread across gene structure
(Fig. 1a and Supplementary Fig. 1a). Of these peaks, 201 genes
were identiﬁed with differential expression in Th9 cells based on a
transcriptome generated from RNA-seq analysis of Th9 gene
expression (Fig. 1b). A more detailed analysis of the Il9 locus
identiﬁed ﬁve occupancy peaks that corresponded to CNS-6
(CNS0), the Il9p (CNS1), and CNS+ 5.5 (CNS2). Further 5′ of
the gene, there were peaks at −20 and −25 kb, with only the −25
kb element showing conservation across species (Fig. 1a). The
−25 kb sequence (termed CNS-25) also resides within a region of
open chromatin in T cells as cataloged by the ENCODE project
(www.encodeproject.org). As an approach to further deﬁne the
function of these elements, we examined binding of p300 and
STAT6, and the presence of H3K4me1 at the locus in Th2 cells
using publically available data33,34. In Th2 cells, which are per-
missive for IL-9 production but have limited expression of the
gene, we observed peaks at CNS-25, CNS-6, and CNS+ 5.5, but
not at the promoter, a result consistent with the observed lack of
gene expression (Fig. 1a). To directly compare the amount of
p300 binding among Th subsets, we performed p300 ChIP on Th
cells differentiated in vitro using polarizing culture conditions.
We focused on Th2 and Treg cells that are derived in vitro with
IL-4 and transforming growth factor beta (TGFβ), respectively as
these cytokines in combination result in Th9 differentiation. As a
control, we included Th cells cultured in the absence of any
exogenous cytokines (Th0). We observed that p300 binding was
most robust in Th9 cells, and at the Il9p and CNS-25 (Fig. 1c, d).
To simplify subsequent presentation of ChIP data, control Ig
values, as indicated in Fig. 1d, have been subtracted from the data
presented rather than showing separately. To demonstrate that
p300 binding to the locus was functionally important, we dif-
ferentiated Th9 cells in vitro in the presence or absence of a p300
inhibitor. Culture with the p300 inhibitor decreased IL-9 (Fig. 1e).
Transcription factor and enhancer activity at Il9 CNS-25. The
Il9 CNS-25 spans ~750 bp and contains two smaller regions with
more extensive conservation that are 286 and 195 bp in length
(Fig. 1a and Supplementary Fig. 1b). Within those segments there
are evolutionarily conserved binding sites for STAT proteins,
GATA proteins, Smads, Forkhead family members, and an AP-1/
IRF consensus element that binds BATF and IRF4 (Fig. 1a and
Supplementary Fig. 1b).
To directly test transcription factor binding at the locus in
primary T cells, we performed ChIP assays for IRF4, BATF,
STAT5, STAT6, PU.1, GATA3, and Foxo1. With the exception of
PU.1, which bound predominantly to the promoter region, all of
the transcription factors showed binding peaks at CNS-25 in Th9
cells (Fig. 2a). All transcription factors also bound the promoter,
although binding of a subset including GATA3 and Foxp1 was
not restricted to Th9 cells (Fig. 2a). Binding of other transcription
factors was strongest in Th9 cells at the Il9p and CNS-25,
although STAT5 also bound the CNS-25 in Treg cultures
(Fig. 2a). We then examined histone modiﬁcations at the locus,
observing greater H3K4me1, a modiﬁcation associated with active
enhancers35, at CNS-25 in Th9 cells (Fig. 2b). In contrast,
H3K4me3, a modiﬁcation associated with gene promoters, was
observed at the Il9p with only minimal amounts at CNS-25
(Fig. 2b). Reciprocal modiﬁcations of H3K27 that are associated
with gene activation (acetylation) and repression (tri-methyla-
tion) were respectively greatest and least in Th9 cells, with a peak
of H3K27Ac at CNS-25 (Fig. 2b). Conversely, Treg cells had the
least amounts of H3K27Ac and the greatest H3K27me3 across the
locus (Fig. 2b).
A number of proteins are also indicative of higher-order
chromatin structures such as looping when bound to regions of
DNA. Among these are CTCF, Med 1, a component of the
Mediator complex, and Smc1a, a component of the cohesion
complex36–41. Consistent with the involvement of CNS-25 in
regulation of Il9, we identiﬁed binding of all three transcription
factors at CNS-25 and the Il9p and only in Th9 cells (Fig. 2c).
Using the chromosome conformation capture assay (3C), we
further demonstrated DNA looping between CNS-25 and the Il9
Fig. 2 Il9 CNS-25 has enhancer characteristics. Naive CD4+ T cells were isolated from C57BL/6 mice and cultured under Th cell polarizing conditions. On
day 5, cells were harvested for ChIP and 3C analysis (a–d) or chromatin accessibility assay (e, f). a The binding of IL-9-inducing transcription factors at the
Il9 locus in Th cell subsets. b Histone modiﬁcations at the Il9 locus in Th cell subsets. c The binding of DNA loop-mediating proteins at the Il9 locus in Th
cell subsets. d DNA loop between CNS-25 and Il9 promoter in Th9 cells. Il9 promoter was used as an anchor and −26 kb/−23 kb regions are used as
negative controls. e, f Chromatin accessibility assay fold enrichment was calculated by the ratio of Ct values from qPCR reactions of the nuclease-treated
and non-treated samples for the Il9 locus (e) and an irrelevant locus, hemogloblin β chain (Hbb-bs) (f). g The expression of Enhancer RNA near CNS-25 in
Th9 and Th2 cells was measured using qRT-PCR with the indicated primer sets. Data are represented as mean ± SEM from three independent experiments
(n= 4 per group). a–c, e One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p < 0.05, **p < 0.01,
***p < 0.001. d, g A two-tailed Student’s t test was used for pairwise comparisons. *p < 0.05
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promoter in Th9 cells as being greater than in Th2 cells, and
greater than between the promoter and regions adjacent to CNS-
25 (Fig. 2d). Transcription factor binding at these sites might also
indicate increased chromatin accessibility. To test this directly we
performed a nuclease accessibility assay and observed much
greater nuclease access in Th9 cells compared to other Th subsets
(Fig. 2e, f).
To begin to examine the function of CNS-25, we generated a
series of luciferase reporter vector containing CNS-25 in various
positions and orientations, and tested the ability of IRF4 to
activate reporter expression in EL4 cells. IRF4 had modest but
signiﬁcant activity on the Il9p vector, and a similarly modest
ability to induce expression by CNS-25 in either orientation but
upstream of the luciferase gene (Supplementary Fig. 2a). When
CNS-25 was cloned upstream of Il9p, there was a synergistic
activation of reporter activity by IRF4, regardless of CNS-25
orientation (Supplementary Fig. 2a). CNS-25 also mediated a
modest transactivation when cloned 3′ of the luciferase gene, and
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further enhanced the ability of the Il9p to activate when cloned on
opposite sides of the reporter gene (Supplementary Fig. 2a). CNS-
25 signiﬁcantly increased Il9p reporter activity in both Th0 and
Th9 cells, but to a greater degree in Th9 cells (Supplementary
Fig. 2b). The data suggest that CNS-25 can enhance Il9 promoter
activity in primary T cells.
To further examine activity of the enhancer, we examined
enhancer RNA (eRNA) transcripts that are commonly found at
active transcriptional elements42–45. These long non-coding
RNAs that are thought to contribute to gene expression are
indicative of active regulatory elements. With all six primer sets
that ampliﬁed sequences both 5′ and 3′ of CNS-25 there was
greater transcription observed in Th9 cells than in Th2 cells
(Fig. 2g), suggesting that it was more transcriptionally active in
IL-9-expressing cells. Together, these data strongly suggest that
Il9 CNS-25 is an important regulatory element in the Il9 gene.
Germline deletion of the Il9 CNS-25 element. To directly
demonstrate that Il9 CNS-25 is an important Il9 regulatory ele-
ment, we generated mice that had a deletion of 1.8 kb in the Il9
locus including the CNS-25 element (Supplementary Fig. 3a).
Homozygous Il9ΔCNS-25 mice developed normally and had nor-
mal numbers and percentages of immune cells in spleen and
lymph nodes. To determine if the deletion of CNS-25 affected IL-
9 production, we differentiated naive CD4+ T cells from WT and
Il9ΔCNS-25 mice. We observed IL-9 production as assessed by
intracellular staining to be decreased by 75% in the absence of
CNS-25 (Fig. 3a, b). Similar decreases were observed using
enzyme-linked immunosorbent assay (ELISA) to measure accu-
mulation and quantitative reverse transcription-PCR to measure
Il9 mRNA (Fig. 3c, d). This effect was speciﬁc for Il9 as there was
no signiﬁcant difference in expression between WT and Il9ΔCNS-
25 Th9 when examining other cytokine production, transcription
factors that are required for IL-9 production, or transcription
factors that repress Il9 expression (Fig. 3c, e, and Supplementary
Fig. 3bc). Additionally, the next closest gene to CNS-25, Fbxl21,
was not detectably expressed in T cells or MCs, and expression in
brain tissue was not altered by CNS-25-deﬁciency (Supplemen-
tary Fig. 3d).
Th9 culture conditions can also promote IL-9 production from
CD8+ T cells46,47, and the requirement for Il9 CNS-25 for
expression in Tc9 cells was assessed. WT and Il9ΔCNS-25 CD8+
T cells cultured with TGFβ and IL-4 showed induction of IL-9
that was completely dependent upon CNS-25 (Fig. 3f, g, and
Supplementary Fig. 3e). However, expression of Ifng and other
Tc-associated genes were not altered (Supplementary Fig. 3f‒h).
IL-9 can also be produced by other Th subsets. To assess if
CNS-25 deﬁciency similarly affects IL-9 in other subsets, naive
CD4+ T cells from WT and Il9ΔCNS-25 mice were differentiated
under Th1, Th2, Th17, or Treg cell inducing conditions.
Differentiation of other subsets was normal as Th1 and Treg
cell expression of Ifng and Tbx21, or Il10 and Foxp3, was not
altered by CNS-25 deﬁciency (Supplementary Fig. 3i‒l). In
Th1 cells we observed very low levels of IL-9 that were not
altered by CNS-25 deﬁciency (Fig. 3d). We could not detect
intracellular IL-9 in Treg cultures, but the limited amount of Il9
mRNA was dependent on CNS-25 (Fig. 3d). In Th17 cultures, the
hallmark Th17 cytokine production was not affected but we
observed a 90% decrease in IL-9 production in the absence of
CNS-25, similar to what was observed in Th9 cells (Fig. 3h–j and
Supplementary Fig. 3m‒o). CNS-25 deﬁciency did not affect IL-4
production, but interestingly increased IL-9 production in Th2
cells (Fig. 3k–m and Supplementary Fig. 3p‒r), suggesting that a
Th2 transcription factor is actively repressing Il9 expression
through the CNS-25 element. Together, these results suggest that
CNS-25 speciﬁcally promotes Il9 expression in Th9 and Th17
cells, but mediates repression of Il9 in Th2 cells.
Il9 locus function in the absence of CNS-25. To further assess
how CNS-25 deﬁciency affected the Il9 locus, we performed ChIP
assays for histone modiﬁcations. We observed that in the absence
of CNS-25, H3K4 tri-methylation and H3K27 acetylation were
diminished at CNS-6 and the Il9p (Fig. 4a). In contrast, H3K27
tri-methylation was not different at CNS-6 and the Il9p but was
increased at non-conserved sites upstream of the gene (Fig. 4a).
We further observed a general pattern of decreased transcription
factor binding at the Il9p in the absence of CNS-25, with sig-
niﬁcant decreases in STAT5, STAT6, IRF4, BATF, and PU.1
(Fig. 4b).
We further tested the “openness” of the locus using the
nuclease accessibility assay. Th9 cells were differentiated from
WT and Il9ΔCNS-25 mice and isolated nuclei were treated with a
nuclease cocktail. In cells that lacked CNS-25, accessibility at the
Il9p was signiﬁcantly decreased without an effect at a control
locus (Fig. 4c, d). These data suggest that in the absence of CNS-
25, the Il9 locus has a more “closed” conﬁguration in Th9 cells.
The ability of transcription factors such as IRF4 and BATF to
activate the Il9 locus is dependent on the accessibility of the locus,
as they do not activate Il9 in Th2 or Th17 cells18. To test the
ability of IRF4 and BATF to transactivate the Il9 locus in the
absence of CNS-25, Th9 cells differentiated from WT and
Il9ΔCNS-25 mice were transduced with retroviruses ectopically
expressing IRF4 or BATF. In the absence of CNS-25 the basal
amount of IL-9 was decreased, consistent with previous data
(Fig. 4e, f). Transduction of IRF4 or BATF into WT cells
increased the amount of IL-9 production (Fig. 4e, f). Importantly,
both BATF and IRF4 transduced into Il9ΔCNS-25 Th9 cells were
also able to increase IL-9 production (Fig. 4e, f). In BATF-
transduced cells, the amount observed was similar to that in
control transduced WT cells (Fig. 4e, f). Moreover, while BATF
and IRF4 transduction did not overcome the loss of CNS-25 in
the absolute amount of IL-9 produced, the fold induction by
Fig. 3 CNS-25 deletion impairs IL-9 production in Th9 cells. Naive CD4+ T cells were isolated from wild-type (WT) or Il9ΔCNS-25 mice and cultured
different Th cell polarizing conditions. On day 4, cells were harvested for analysis. For intracellular staining, cells were restimulated with PMA/ionomycin
for 6 h. Cells were restimulated with anti-CD3 for 6 h or overnight to assess cytokine production using qRT-PCR or ELISA, respectively. a–c IL-9 expression
in WT or Il9ΔCNS-25 Th9 cultures by ﬂow cytometry (representative dot plots in a and average percentage in b), or ELISA (c). d Il9 expression of in all Th
cell subsets relative to Th9 cells. The inset shows an expanded scale to demonstrate differences in the indicated Th subsets. e Cytokine mRNA expression
in Th9 cells. f, g CD8+ T cells were isolated from WT or Il9ΔCNS-25 mice and cultured under Tc9 cell polarizing conditions. On day 2, cells were harvested
and restimulated with PMA/ionomycin for 6 h to assess cytokine production using intracellular staining. Representative dot plots in f and average
percentages in g. h–j IL-9 expression in WT or Il9ΔCNS-25 Th17 cultures by ﬂow cytometry (representative dot plots in h and average percentage in i), or
ELISA (j). k–m IL-9 expression in WT or Il9ΔCNS-25 Th2 cultures by ﬂow cytometry (representative dot plots in k and average percentage in l), or ELISA
(m). a, f, h, k Numbers indicate the average percentage ± SEM of T cells from 3 mice. All gene expression was normalized to β2m expression. Data are
represented as mean ± SEM from three independent experiments (n= 3 per group). A two-tailed Student’s t test was used for pairwise comparisons. *p <
0.05, **p < 0.01, ***p < 0.001
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either transcription factor was the same in WT and Il9ΔCNS-25
Th9 cells, suggesting that ectopic expression of the transcription
factors can still activate the locus by binding to the promoter.
Constitutively active STAT5 (caSTAT5) ectopic expression
signiﬁcantly increased IL-9 production in both WT and
Il9ΔCNS-25 Th9 cells to a greater degree than IRF4 or BATF but
IL-9 production was still not equal to WT transduced cells
(Fig. 4g). Thus, while all transcription factors tested are able to
function through the Il9 promoter and other remaining elements,
overexpression does not overcome the contribution of the CNS-
25 element.
Il9 CNS-25 deﬁciency in innate immune cells. A number of
other cell types also express Il9 including MCs, basophils, and
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ILCs48–51. To determine if Il9 CNS-25 was active in cells other
than CD4+ T cells, we examined IL-9 production in these
populations in the absence of CNS-25. ILC2 are both IL-9 pro-
ducers and IL-9 responsive, with homeostasis depending on
IL-948,49. To determine if ILC2 numbers or IL-9 production were
affected by CNS-25 deﬁciency, WT and Il9ΔCNS-25 mice were
injected intranasally with IL-33 as previously described48. We
observed no differences in either total ILC or ILC2 (Lin−, CD45+,
KLRG1+, Sca1+, Thy1.2+, and ST2+) accumulation in the lung
and no difference in IL-9 production (Fig. 5a and Supplementary
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Fig. 4a, b).This suggests that Il9 CNS-25 is not required for ILC2
IL-9 production, and that the amount of IL-9 lost in Il9ΔCNS-25
mice is not sufﬁcient to negatively affect ILC2 numbers in this
system.
To determine if IL-9 production is dependent on CNS-25 in
MCs and the related basophil cell population, we differentiated
each cell type from bone marrow of WT and Il9ΔCNS-25 mice. Cell
growth of MCs and basophils in culture was not altered by CNS-
25 deﬁciency, and the modest increases in Fc receptors and
CD49b expression on the surface of Il9ΔCNS-25 cells are unlikely
to be biologically signiﬁcant (Supplementary Fig. 4c‒e). MCs and
basophils from Il9ΔCNS-25 mice demonstrated diminished IL-9
production compared to WT cells with no changes in IL-6
production (Fig. 5b, c). Bone marrow-derived MC and basophil
production of IL-9, like Th9 cells, was dependent on p300
(Fig. 5d). Peritoneal MCs and basophils were also isolated from
Il9ΔCNS-25 mice treated with IL-33 as in Fig. 5a and observed to
produce less IL-9 than WT cells (Fig. 5e). To further characterize
the effects of Il9 CNS-25 deﬁciency on MC homeostasis we
enumerated mature and precursor cells using established
markers52. MC precursor numbers in the bone marrow and
MC numbers in the bone marrow and peritoneal cavity were
signiﬁcantly decreased in Il9ΔCNS-25 mice (Fig. 5f, h). In contrast,
basophil/MC precursors in the spleen, and mature basophils in
the blood and peritoneal cavity of Il9ΔCNS-25 mice were
indistinguishable from WT mice (Fig. 5g, h). To determine if
the decrease in MC numbers had an effect on function, we
performed a passive systemic anaphylaxis assay and observed that
Il9ΔCNS-25 mice had signiﬁcantly less temperature change (area
under the curve, p= 0.043) and signiﬁcantly less serum IL-6 at
the termination of the assay (Fig. 5i). Together, these data
indicate that Il9 CNS-25 is a critical regulator of IL-9 in T cells,
MCs, and basophils, but not ILCs.
Il9 CNS-25 deﬁciency in vivo. To continue to test the effects of
CNS-25-deﬁciency in vivo, WT and Il9ΔCNS-25 mice were
exposed to Aspergillus fumigatus extract over a period of 3 weeks
(Fig. 6a). Although there were no differences in the overall cell
and eosinophil number in the bronchoalveolar lavage (BAL),
analysis of CD4+ T cells in the BAL and lung revealed that the
proportion of IL-9-secreting T cells was signiﬁcantly decreased in
mice lacking CNS-25 (Fig. 6b–d). In contrast, there were no
differences in the percentages of IL-17A-positive cells (Fig. 6d).
To further assess the effects of CNS-25 deﬁciency on the
inﬂammatory process, we assessed additional parameters of
allergic inﬂammation. Mucus production in the lung, as assessed
by periodic acid–Schiff (PAS) staining of tissue and Muc5ac and
Clca3 expression, was signiﬁcantly decreased in Il9ΔCNS-25 mice
compared to WT mice (Fig. 6e, f). Consistent with mucus
production having a major contribution to airway reactivity in
mice53, Il9ΔCNS-25 mice had diminished methacholine reactivity
compared to WT mice (Fig. 6g). Consistent with MC accumula-
tion in allergic inﬂammation being dependent on IL-9 and Th9
cells54,55, there were signiﬁcantly diminished numbers of MCs in
the trachea from Il9ΔCNS-25 mice, compared to WT mice (Fig. 6h).
Together, these data indicate that Il9 CNS-25 controls IL-9
production in vivo and that CNS-25-dependent IL-9 controls
mucus production, MC accumulation, and airway hyperreactivity.
Function of the human IL9 CNS. By virtue of Il9 CNS-25 being a
CNS, there is a homologous sequence 18 kb upstream of the
human IL9 gene (Fig. 7a). However, there is the possibility that
the human and mouse genes encoding IL-9 might be regulated
differently. Although IL9 is linked (3.2 Mb away) to the IL4-IL13-
IL5 locus in the human genome on chromosome 5, Il9 is on a
separate chromosome (chromosome 13) from the Il4-Il13-Il5
locus (chromosome 11) in the mouse genome. Thus, to directly
determine if IL9 CNS-18 functioned similarly to Il9 CNS-25, we
ﬁrst performed ChIP assays for histone modiﬁcations. Naive CD4
+CD45RA+ T cells were isolated as described in methods and the
purity of naive T cells after magnetic separation was determined
to deﬁne contamination from terminally differentiated effector
memory cells re-expressing CD45RA (TEMRA). The puriﬁed
population was over 95% CD4+CD45RA+ and the percentage of
KLRG1+ and/or CD57+ cells, markers of TEMRA, was <1.5%
(Supplementary Fig. 5b). After in vitro differentiation under
polarizing conditions, we observed that IL9 CNS-18 was enriched
for monomethyl-H3K4 and acetyl-H3K27 in human Th9 cultures
compared to Th0 cells (Fig. 7a). To more directly test the function
of IL9 CNS-18, we used a Cas9-EGFP fusion protein-encoding
lentivirus that also expressed two guide RNAs targeting sequences
surrounding CNS-18 to infect human Th9 cell cultures. Gating on
the green ﬂuorescent protein (GFP)-positive cells, we observed
that deletion of CNS-18 reduced IL-9 production among multiple
donors (Fig. 7b, c). PCR veriﬁed deletion of the CNS-18
sequences and the percent deletion correlated signiﬁcantly with
the percent decrease in IL9 expression (Fig. 7d). Importantly,
deletion of CNS-18 had no effect on the expression of cytokines;
IL10 and IL21, which are produced by Th9 cells (Fig. 7e) or IL5,
IL13, and IL3, which are linked to same chromosome with IL9
(Supplementary Fig. 5a) in transduced cells. IL4 expression was
not detected. Thus, IL9 CNS-18 is an important regulatory ele-
ment of the IL9 gene in human Th9 cells.
Discussion
Although IL-9 can be produced by many cell types within the
context of pathogen immunity, tumor immunity, and
Fig. 5 CNS-25 deletion impairs IL-9 production in multiple lineages of IL-9-producing cells. a WT and Il9ΔCNS-25 mice were treated i.n. with 0.5 µg of IL-33
for 3 days. Lung ILCs were isolated and restimulated with IL-33. Frequency of ILCs in lung was analyzed by ﬂow cytometry (left) and IL-9 production by
ILCs was analyzed by ELISA (middle) and intracellular staining (right). b, c IL-9 and IL-6 mRNA (b) and protein (c) levels were assessed by qRT-PCR or
ELISA, respectively, in IL-33-stimulated mast cells (MCs) and basophils derived from WT and Il9ΔCNS-25 bone marrow. d MC and basophils derived from
WT and Il9ΔCNS-25 bone marrow were treated with p300i for 1 h prior to stimulation with IL-33. IL-9 production was assessed using ELISA. e WT and
Il9ΔCNS-25 mice were treated i.n. with 0.5 µg of IL-33 for 3 days. Peritoneal cells (left) and white blood cells (WBC) (right) were restimulated with IL-33 and
intracellular IL-9 production was measured in MC and basophils by ﬂow cytometry. f MC (left) and mast cell precursor (MCp) (right) frequencies were
assessed in bone marrow of WT and Il9ΔCNS-25 mice. g Basophil mast cell progenitor frequencies in spleen (left) and basophil frequencies in blood (right)
were analyzed via ﬂow cytometry in WT and Il9ΔCNS-25 mice. h Frequencies of mast cells (top) and basophils (bottom) in peritoneum of WT and Il9ΔCNS-
25 mice. i WT and Il9ΔCNS-25 mice were injected with anti-DNP IgE (50 µg) 16 h before passive systemic anaphylaxis (PSA) (n= 9–10). PSA was induced
by administering 100 µg of DNP-BSA. Core body temperature was measured over 90min period and mice were sacriﬁced. Inset, after sacriﬁce, plasma IL-6
level was measured using ELISA (n= 4). AUC used to compare response in WT and Il9ΔCNS-25 mice (p= 0.043). Unless otherwise stated, all data are
mean ± SEM and representative of at least two independent experiment done in triplicates and statistical signiﬁcance assessed by using unpaired Student’s
t test (*p < 0.05; **p < 0.01; ***p < 0.001). N.D. not detected
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inﬂammatory disease, the regulation of this cytokine is still largely
uncharacterized. In this report we have deﬁned an Il9 regulatory
element, CNS-25, that has all the hallmarks of an enhancer and is
required for normal IL-9 production in multiple cell types
including T cells, MCs, and basophils. Importantly, the function
of this element is conserved in human T cells where the IL9 CNS-
18 is required for optimal IL-9 production in human Th9 cells.
The Il9 CNS-25 element confers multiple levels of speciﬁcity to
the IL-9 gene. Within both human and mouse Th9 cells, CNS-
25/-18 promoted IL-9 expression under standard culture
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conditions, and for mice, IL-9 production in vivo as well. Il9
CNS-25 also promoted IL-9 in MCs, basophils, Th17 cells, Tc9
cells, but surprisingly not in ILCs. The lack of an effect of CNS-25
deletion in ILCs on IL-9 production was observed in cells isolated
from IL-33-treated-mice. This would suggest that Il9 regulation in
ILCs is intrinsically different from other immune cells. Previous
studies have suggested that ILC cytokine loci are primed for
expression to a greater degree than in T cells56,57. Indeed, the Il9
locus had more ATAC-seq peaks in precursor and mature ILC2
than Th2 cells57, and the ATAC-seq proﬁle in ILCs corresponds
to the p300 ChIP-seq proﬁle in Th9 cells. It is possible that other
enhancers can compensate for the loss of Il9 CNS-25 in ILCs, a
common concept in development where disruption of multiple
regulatory elements is needed for a phenotypic change58.
Regardless of the differences in control between ILCs and other
immune cells, the lack of an effect in ILCs further demonstrates
the speciﬁcity of the effects of Il9 CNS-25 deletion.
Also striking was the repressor effect observed on the loss of Il9
CNS-25 in Th2 cells where IL-9 production was increased in
Il9ΔCNS-25 cultures, compared to WT cultures. The amount of IL-
9 produced by Il9ΔCNS-25 Th2 cells is still far less than observed
from Th9 cultures, suggesting that CNS-25 is not the sole factor
controlling the distinction in IL-9 production between these cell
types. Additional factors are clearly promoting Il9 expression in
Th9 cells to a greater degree. However, it does suggest that there
is a transcription factor in Th2 cells, not expressed in Th9 cells,
that binds to CNS-25 and attenuates IL-9 production. While the
identity of this transcription factor is not yet clear, it mirrors one
role of PU.1, which represses Th2 cytokines as it induces IL-9
production16,59,60. Further studies will help to deﬁne this tran-
scription factor and its importance in the balance between Th2
and Th9 cell differentiation.
There are some parallels between these observations and the
recent descriptions of super-enhancers (SEs) at the Il9 locus29.
That report found three SE regions, deﬁned with broad peaks of
acetylated H3K27 and Brd4 binding that seemed to roughly
overlap with CNS+ 5.5, CNS-6, and CNS-25. Xiao et al.29 found
that the CNS+ 5.5 region mediated the OX40-stimulated IL-9
production and observed little effect on OX40-stimulated IL-9
when a region encompassing CNS-25 was deleted. This likely
represents differences between the response elements to OX40
and antigen receptor stimulation and that basal IL-9 production,
in the absence of OX40 stimulation, was low in those studies.
Thus, from the published studies it is impossible to determine if
the region 3-prime of the Il9 gene is important for induction of
IL-9 to other stimuli, or if it controls expression of Il9 in other cell
types. The importance of the CNS+ 5.5 region is interesting in
that it is the least conserved of the CNS regions in the Il9 locus,
being conserved between mouse and humans, but not extensively
with other species28. It would be worth exploring whether
OX40 stimulation of IL-9 was restricted to certain species, or if it
activated the expression through other elements in the Il9 locus in
other species.
Il9 CNS-25 clearly contributes to the overall structure of the Il9
locus. We observed that Il9 CNS-25 is physically linked to the Il9
promoter in a 3C assay. This observation is supported by multiple
proteins indicative of higher-order locus structure including
CTCF, Smc1a, and Mediator complex components that were
bound speciﬁcally in Th9 cells at the Il9p and CNS-25. It is also
possible that deletion of the Il9 CNS-25 element results in
changes to the higher-order structure of the locus, perhaps also
preventing the interaction of other elements with the Il9p. In that
respect, some effects observed in these studies might be secondary
to the impact of CNS-25 on other elements. Still, our results point
to a central role for CNS-25 in establishing IL-9 production.
There is also the possibility that deleting cytokine regulatory
elements might affect IL-9 production by feedback effects. In
mouse cells, it is possible that IL-9 might feedback to control its
own production. However, in experiments that block or supple-
ment IL-9 during in vitro differentiation, we have not observed
any changes in IL-9 production. In human cells, the IL9 CNS-18
is physically linked to other Th2 cytokines and this might
represent another potential indirect effect of deletion of the ele-
ment. However, we detected no IL4 expression in human Th9
cultures, and no signiﬁcant change in the expression of IL5, IL13,
or IL3 upon IL9 CNS-18 deletion, suggesting that this does not
explain the decreases in IL-9 production in human Th9 cells
when CNS-18 is deleted. Together, these data support a role for
this element in speciﬁcally regulating the Il9/IL9 gene.
Il9 CNS-25 binds most of the transcription factors known to
impact IL-9 production16–22,26,61. It is interesting that PU.1 is
unique in binding predominantly to the Il9 promoter perhaps
suggesting that it is one of the initial activating transcription
factors. The ability of Il9 CNS-25 to bind multiple transcription
factors suggests that there might be cooperative functions of the
transcription factors. Indeed, in examining IRF4-deﬁcient and
STAT6-deﬁcient Th9 cells, we see decreases in other transcription
factors bound to the CNS-25 region and decreases in modiﬁca-
tions associated with activated chromatin. We saw similar
cooperative binding between BATF and IRF4 at the Il9 promoter,
and others have seen cooperative binding at the promoter with
IRF4 and Smad proteins25,62. Further studies will more com-
pletely deﬁne these cooperative interactions in detail.
Although Il9 CNS-25 identiﬁed in our studies is clearly
important for IL-9 production, it does not negate the importance
of other elements. The Il9 CNS-6 clearly binds some IL-9-
inducing transcription factors, is a p300-binding peak, and has
enhancer activity in a reporter assay. The Il9 CNS+ 5.5 region is
clearly required for IL-9 induction by OX40 stimulation29. In the
p300 ChIP-seq data, we also observed a p300-binding peak at
Fig. 6 Il9ΔCNS-25 mice have attenuated IL-9 production and airway reactivity in A. fumigatus extract-induced airway inﬂammation. WT and Il9ΔCNS-25 mice
were intranasally challenged with 25 μg of A. fumigatus extract 3 times a week for 21 days. a Schematic of A. fumigatus extract-induced airway inﬂammation
model. b Total cell and eosinophil numbers in the BAL from mice harvested on day 22. c, d BAL and lung cells were restimulated with PMA/ionomycin for
6 h to measure cytokine production using intracellular staining. Representative dot plots (c) and average percentages (d) of IL-9-producing or IL-17-
producing CD4+ T cells in BAL (top) and lung (bottom). Cells for ﬂow cytometric analysis were gated on lymphocyte size and granularity, and the
expression of CD4 and TCRβ. Data are mean ± SEM of 5 mice per group. A two-tailed Student’s t test was used for pairwise comparisons. *p < 0.05, **p <
0.01, ***p < 0.001. e Representative images of PAS staining of inﬂamed lung tissue. Scale bars= 100 μm. f Muc5ac and Clca3 expression in the lung tissues.
Gene expression were normalized to β2m expression. g WT (n= 7) and Il9ΔCNS-25 (n= 9) mice were treated intranasally with 25 µg A. fumigatus extract
three times a week for 3 weeks. RI was measured in response to methacholine challenge 2 h after the last intranasal antigen treatment. Data are mean ±
SEM of WT (n= 7) and Il9ΔCNS-25 (n= 9). One-way ANOVA with a post hoc Tukey test was used to generate p values for multiple comparisons (**p <
0.0021, ****p < 0.0001). h Number of mast cells in trachea after Toluidine blue staining of trachea counted from two ﬁelds of each specimen and averaged.
d, f, h Data are mean ± SEM of 5 mice per group and representative of two independent experiments. A two-tailed Student’s t test was used for pairwise
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07202-0 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:4803 | DOI: 10.1038/s41467-018-07202-0 | www.nature.com/naturecommunications 11
about −20 kb from the Il9 TSS. Although this region is not
evolutionarily conserved, it might still contribute to Il9 regulation
and perhaps similar elements can be identiﬁed in other species.
We did look across a larger window (±100 kb) on either side of
the Il9 gene and did not see other Th9 p300 peaks or peaks from
other Th subsets that identiﬁed other potential regulatory ele-
ments. How all of these elements function in concert remains to
be further explored.
There were multiple effects of diminished IL-9 in vivo,
although IL-9 production in Th cells, MCs, and basophils was not
completely ablated, and IL-9 production appeared normal in
ILCs. In a passive systemic anaphylaxis model, Il9ΔCNS-25 mice
showed less severe anaphylactic responses and serum cytokine
responses. This could be due both to diminished MC homeostasis
as well as effects of IL-9 directly on mature MCs and basophils. In
the Aspergillus extract model of allergic airway disease Il9ΔCNS-25
mice demonstrated attenuate mucus production, decreased
airway reactivity, and decreased MC accumulation in the trachea.
In contrast, there was no decrease in the overall inﬁltration into
the airways or IL-17-secreting CD4 T cells in the lung, suggesting
that the observations were due to speciﬁc effects of IL-9 in allergic
inﬂammation and not because of overall diminished inﬂamma-
tion. Thus, the Il9ΔCNS-25 mice present a useful model to further
explore IL-9-speciﬁc responses in allergic disease.
IL-9 is a critical cytokine in immunity to helminthic parasites,
tumor immunity, and in inﬂammatory diseases including auto-
immunity and allergic inﬂammation. Understanding the regula-
tion of IL-9 will allow manipulation of signals and transcription
factors that can control IL-9 production to alter the course of
disease, and potentially amplify the ability of Th9 cells to mediate
beneﬁcial immunity. The identiﬁcation of Il9 CNS-25 as a cen-
trally important control element of the IL-9 gene in multiple cell
types, and the ﬁnding that function of this element is conserved
in human T cells, suggests that these ﬁndings represent an entry
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07202-0
12 NATURE COMMUNICATIONS |          (2018) 9:4803 | DOI: 10.1038/s41467-018-07202-0 | www.nature.com/naturecommunications
point to an ability to control IL-9 production in the context of
immunity and disease.
Methods
Mice. All mice were C57BL/6 background. CNS-25-deleted mice (Il9ΔCNS-25) were
generated by CRISPR/Cas9-mediated gene editing (Taconic, Germany) (Supple-
mentary Table 1). Mice were maintained under speciﬁc pathogen-free conditions.
Experiments were performed with Il9ΔCNS-25 mice and their littermate controls.
Other experiments were done with C57BL/6 female and/or male mice purchased
from the Jackson Laboratory. All experiment were done with 6- to 12-week old
mice. All experiments were performed with the approval of the Indiana University
Institutional Animal Care and Use Committee.
Human. De-identiﬁed peripheral blood mononuclear cells (PBMCs) from buffy
coat blood packs were obtained from the Indiana Blood Center. Studies were
approved by the Institutional Review Board.
In vitro mouse T-cell differentiation. Naive CD4+CD62L+ T cells from mice
were positively selected from the enriched CD4+ T cells from spleen and lymph
nodes using MACS beads and columns (Miltenyi Biotec). Naive CD4+CD62L+
T cells were activated with plate-bound anti-CD3 (2 Units/ml−1 145-2C11;
BioXCell) and soluble anti-CD28 (0.5 μg ml−1; BD Pharmingen) in complete
culture media (cRPMI), Roswell Park Memorial Institute 1640 (RPMI 1640,
ThermoFisher Scientiﬁc) containing 10% fetal bovine serum (FBS, Atlanta Biolo-
gicals), 1% antibiotics (penicillin and streptomycin/stock; Pen 5000 Units ml−1,
Strep 5000 μg ml−1), 1 mM sodium pyruvate, 1 mM L-glutamine, 2.5 ml of non-
essential amino acids (stock; 100×), 5 mM HEPES (all from LONZA), and 57.2 μM
2-mercapoethanol (Sigma-Aldrich), to generate Th0 cells (10 U hIL-2) or with
additional cytokines (all from PeproTech) and antibodies (all from BioXCell) to
generate Th2 cells (20 ng ml−1 IL-4; and 10 μg ml−1 anti-interferon gamma (IFNγ)
XMG), Th9 cells (20 ng ml−1 IL-4, 2 ng ml−1 hTGF-β1, and 10 μg ml−1 anti-IFNγ
XMG), Treg cells (5 ng ml−1 hTGF-β1, 10 U hIL-2, 10 μg ml−1 anti-IFNγ, and 10
μg ml−1 anti-IL-4), Th17 cells (100 ng ml−1 IL-6, 2 ng ml−1 hTGF-β1, 10 μg ml−1
anti-IFNγ, and 10 μg ml−1 anti-IL-4), and Th1 cells (20 ng ml−1 IL-12, 10 U hIL-2,
and 10 μg ml−1 anti-IL-4 11B11) culture conditions. Cells were grown at 37 °C
under 5% CO2 and were expanded after 3 days with original concentration of
cytokines in fresh medium. For p300i studies, cells were treated with 20 nM of
p300i (SGC-CBP30, TOCRIS) on day 3. Cells were harvested on day 4 or 5 for
analysis.
CD8+ T cells from mice were positively selected using CD8a (Ly-2) microbeads
(Miltenyi Biotec). CD8+ T cells were activated with plate-bound anti-CD3 (2 μg ml
−1 145-2C11; BioXCell) and soluble anti-CD28 (0.5 μg ml−1; BD Pharmingen) in
cRPMI to generate Tc9 cells (20 ng ml−1 IL-4, 2 ng ml−1 hTGF-β1, and 10 μg ml−1
anti-IFNγ XMG). Cells were grown at 37 °C under 5% CO2 and harvested on day 2
for analysis.
In vitro human T-cell isolation and differentiation. PBMCs were isolated from
de-identiﬁed buffy coat blood packs (Indiana Blood Center, IN) by density gradient
centrifugation using Ficoll-Paque (GE Healthcare). Human naive CD4+CD45RA+
T cells were isolated from human PBMCs using magnetic separation (Miltenyi
Biotec). These cells were activated with an equal ratio of receptor crosslinking bead,
Dynabead human T-activator CD3/CD28 (ThermoFisher Scientiﬁc) in cRPMI to
generate Th0 cells (10 U hIL-2) and Th9 cells (20 ng ml−1 hIL-4, 2 ng ml−1 hTGF-
β1, and 10 μg ml−1 anti-IFNγ), and grown at 37 °C under 5% CO2. Cells were
harvested on day 4 or 5 for analysis.
In vitro MC and basophil generation. To generate MCs and basophils, bone
marrow cells from WT and Il9ΔCNS-25 mice were isolated and red blood cells
(RBCs) were lysed using Ammonium-Chloride-Potassium (ACK) lysis buffer
(LONZA). Cells were cultured in cRPMI with IL-3 (10 ng ml−1) and stem cell
factor (SCF; 30 ng ml−1) (all from BioLegend) for MCs or 20 ng ml−1 of IL-3 for
basophils. After 7 days of culture, basophils were isolated using anti-PE CD49b
microbeads and MCs were allowed to mature for 21 days. Mature MCs and
basophils were set to 1 × 106 cells per ml in 10 ng ml−1 of both IL-3 and SCF and
stimulated with 50 ng ml−1 of IL-33 (BioLegend) for 4 h (quantitative real-time
PCR; qPCR) or 16 h (ELISA). For p300i work, MCs and basophils were cultured as
stated above and were treated with 20 nM of p300i (SGC-CBP30, TOCRIS) 1 h
before stimulation with 50 ng ml−1 of IL-33 for 16 h.
Innate cell isolation. For lung ILC studies, WT and Il9ΔCNS-25 mice were treated
intranasally (i.n.) with 0.5 µg of IL-33 for 3 days. For single-cell suspension, lung
tissues were minced and incubated with 0.5 mg ml−1 of collagenase A (Roche) in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) at 37 °C for 45 min. After grinding
tissues with mesh stainless steel strainer, RBCs were removed by ACK lysing buffer
(LONZA) and reaction was stopped by adding buffer (phosphate-buffered saline
(PBS) with 0.5% bovine serum albumin (BSA)), cells were washed with the buffer
followed by ﬁltering through 70 μm nylon mesh to remove debris. Lung cell sus-
pension was lineage-depleted using lineage depletion kit and biotinylated
antibodies (lineage depletion kit and CD11c, CD19, DX5, and NK1.1) (all from
Miltenyi Biotec). For intracellular IL-9 measurement, the lineage-negative cells
were restimulated with 50 ng ml−1 of IL-33 for 5 h and treated with monensin for
2 h. These cells were stained with Thy1.2 and IL-9. For detection of intracellular
IL-9, these cells were selected as viability dye-negative and Thy1.2-positive via ﬂow
cytometry. For ELISA, Thy1.2-positive cells were selected as follows. Cells were
stained with Thy1.2-PE and isolated using anti-PE beads according to the manu-
facturer’s instruction (Miltenyi Biotec). Cells were restimulated with 50 ng ml−1 of
IL-33 in cRPMI for 16 h.
For peritoneal cell isolation, WT and Il9ΔCNS-25 mice were treated i.n. with 0.5
µg of IL-33 for 3 days. Peritoneal cells were isolated by washing the peritoneal
cavity using PBS. White blood cells (WBC) were isolated by collecting blood from
animals using cardia puncture. Blood RBCs were lysed using ACK lysis buffer
(LONZA). Peritoneal cells and WBC were cultured in cRPMI with IL-3 and SCF
supplement (10 ng ml−1 for both). Cells were restimulated immediately with 50 ng
ml−1 of IL-33 and intracellular IL-9 production was measured in MC and
basophils via ﬂow cytometry. MCs were gated as FcϵR1 and c-kit double-positive
and basophils were gated as FcϵR1 and CD49b double-positive.
To determine basophil and MC frequencies, bone marrow cells and peritoneal
cells were isolated as described above. The frequencies of basophils and MCs and
their progenitors were gated as follows. Mature MCs in bone marrow and
peritoneum were gated as FcϵR1 and c-kit double-positive. Mature basophils in
blood and peritoneum were gated as FcϵR1 and CD49b double-positive. Bone
marrow MC progenitors (MCps) were gated as lineage-negative (CD5, B220,
CD11b, CD27, anti-Gr-1(Ly6G/C), Ly6C, Sca1, Ter119, CD19, and NK1.1)
FcϵR1lowc-Kit+ST2+β7+. Basophil MCp in the spleen was gated as lineage-
negative (B220, CD3, Ly6C/G, NK1.1, GR1, Ter119, and CD5) c-Kit+FcγRII/
IIIhiβ7hiST2+. Basophils and MC and their progenitor frequencies were identiﬁed
using previously published surface marker criteria63.
Retrovirus production and transduction. Platinum E cells were grown in 10 ml of
DMEM 1640 with 10% FBS and 1% antibiotics in a 100 mm tissue culture dish.
When conﬂuency reached 80–90%, cells were transfected with control vector or
retroviral vector containing BATF, IRF4, or caSTAT5 open reading frame using
Lipofectamine 3000 (ThermoFisher Scientiﬁc) according to the manufacturer’s
instructions. After 24 h of transfection, the media was collected for retroviral
transduction or stored at −80 °C for subsequent use.
Activated mouse CD4+ T cells were infected on day 1 with retrovirus
containing control or expressing the interested gene by centrifugation at 2300 rpm
at 32 °C for 90 min in the presence of 8 μg ml−1 polybrene (Sigma-Aldrich). After
spin infection, the supernatant was replaced with the fresh Th cell condition media.
Cells were expanded on day 3 and analyzed on day 4 or 5.
CRISPR/Cas9 plasmid construct. PX330A_D10A-1 × 2 (Addgene #58772) was
modiﬁed by adding ClaI site in front of hU6 promoter, termed as “new
pX330A_D10A-1 × 2”. gRNAs were designed using the Zhang lab’s online tool
(http://crispr.mit.edu/). After annealing of gRNA oligos, the gRNA duplexes were
cloned to modiﬁed pX330A_D10A-1 × 2 and pX330S-2 (Addgene #58778) using
BbsI (BpiI) (Supplementary Table 2). Through Golden gate assembly using Eco31I,
the modiﬁed pX330A_D10A-1 × 2, which contains gRNA cassette containing two
hU6 promoter and two gRNAs was generated. By using Cla1 and Kpn1, the gRNA
cassette from this vector was inserted to new lentiCRISPR v2 (modiﬁed from
lentiCRISPR v2, Addgene #52961, by adding new cloning site containing Cla1 and
Kpn1) using Cla1 and Kpn1. Finally, a DNA element containing gRNA cassette of
this new lentiCRISPR v2 was replaced with lentiCas9-EGFP (Addgene #63592)
using Not1 and Nhe1. Plasmids and gRNA sequences are listed in Supplementary
Table 2 and 3.
Lentivirus production and infection. Human embryonic kidney 293T cells were
grown with 10 ml of DMEM 1640 with 10% FBS and 1% antibiotics in a 100 mm
tissue culture dish. When conﬂuency reached 95–99%, cells were transfected with
lentiviral vectors expressing Cas9 and gRNAs targeting hIL9 CNS-18 or GM38602
as a negative control using Lipofectamine 3000. After 24 h of transfection, the virus
was collected and concentrated with Lenti-X-concentrator (Takara Bio) according
to the manufacturer’s instructions.
Day 1 cultured human T-cells were infected by the lentivirus using Retronectin
(Takara Bio) according to the manufacturer’s instructions. Cells were harvested on
day 4 or 5 for analysis using ﬂow cytometry or sorted by ﬂuorescence-activated cell
sorter (FACS; BD FACSAria) based on enhanced GFP (EGFP) for gene expression
analysis.
A. fumigatus extract-induced allergic airway inﬂammation. Mice were chal-
lenged intranasally with A. fumigatus (Greer Laboratories) extract 3 days a week for
21 days. A. fumigatus (25 μg) extract was diluted with PBS (20 µl) and administered
into the nose. Mice were sacriﬁced 1 day after ﬁnal intranasal challenge. BAL cells
were collected by lavaging the lungs with 1 ml PBS. BAL and lung single-cell
suspensions were stimulated with phorbol 12-myristate 13-acetate (PMA) and
ionomycin for 6 h with monensin added after 2 h to assess cytokine production
using intracellular staining. For ILC2 analysis, total lung cells were stained with
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lineage-positive staining cocktail (BD Pharmingen), CD45, KLRG1, Sca1, Thy1.2,
and ST2.
For airway resistance, 1 day after ﬁnal intranasal challenge, mice were subjected
to increased doses of methacholine and airway resistance was measured using
plethysmograph chambers with a ventilator (Elan Series Mouse RC Site; Buxco
Electronics) and BioSystem XA software (Buxco Electronics).
For histology, lungs and trachea were excised from the thoracic cavity followed
by ﬁxation with 4% neutral-buffered formaldehyde (ThermoFisher Scientiﬁc).
Tissues were embedded in parafﬁn, sectioned, and stained with the PAS for lung
tissue or toluidine blue staining for trachea.
Passive systemic anaphylaxis. For anaphylaxis experiment WT and Il9ΔCNS-25
mice were intraperitoneally (i.p.) injected with 200 µg of anti-DNP IgE (provided
by Dr. Basar Bilgicer, Notre dame University) 16 h before they were i.p. challenged
with 50 µg of DNP-BSA (Sigma-Aldrich). Core body temperature of animals was
measured for 90 min using rectal thermometer (Braintree Scientiﬁc, Inc.) at which
point plasma was collected via cardiac puncture to measure cytokine levels via
ELISA.
Quantitative real-time PCR. Total RNA was extracted using TRIzol reagent
(ThermoFisher Scientiﬁc) and reverse transcribed using cloned Avian Myelo-
blastosis Virus reverse transcriptase (ThermoFisher Scientiﬁc). For qPCR, Taqman
real time PCR assay (ThermoFisher Scientiﬁc) or SYBR green master mix (Applied
Biosystems) was used for gene expression analysis. Gene expression was normal-
ized to housekeeping gene expression (β2-microglobulin). The relative gene
expression was calculated by the change-in-threshold (2−ΔCT) method. All
experiments were performed in duplicate in two independent experiments and
results are presented as standard error of means of biological replicates. Taqman
probes and eRNA primer sequences are listed in Supplementary Table 4 and 5.
Flow cytometric analysis. For cytokine staining, in vitro-cultured CD4+ T cells
were stimulated with PMA (Sigma-Aldrich) and ionomycin (EMD Millipore) for 2
h followed by monensin (BioLegend) for a total of 6 h. After ﬁxation with 4%
formaldehyde for 10 min at room temperature (RT), cells were washed two times
with FACS buffer (PBS with 0.5% BSA). For transcription factor staining, cells were
ﬁxed with Foxp3/Transcription factor ﬁxation buffer (eBioscience) at 4 °C in dark
for 30 min or overnight. Fixed cells were permeabilized with permeabilization
buffer (eBioscience), and stained for cytokines and transcription factors with
ﬂuorochrome-conjugated antibodies (1:200 dilution) at 4 °C in dark for 1 h. Stained
cells were washed two times with FACS buffer and resuspended with 500 μl of
FACS buffer for ﬂow analysis. Fluorescent antibodies for ﬂow cytometric analysis
are listed in Supplementary Table 6.
Enzyme-linked immunosorbent assay. Cytokine capturing antibodies were
coated on 96-well plate (NUNC) with coating buffer (dH2O with 0.1 M NaHCO3
pH 9) and incubated at 4 °C overnight. After blocking the coated plate for 1 h with
ELISA buffer (PBS with 2% BSA), diluted samples (10- to 100-fold diluted with
ELISA buffer) and standard cytokines were added and incubated at 4 °C overnight.
After washing, the plate was incubated with biotinylated secondary antibody at RT
for 1 h followed by incubation with avidin-alkaline phosphatase (Sigma) at RT for
1 h. After washing the plate, p-Nitrophenyl Phosphate (Sigma-Aldrich) was added
and measured with the Biorad Microplate 680 ELISA reader. Primary and sec-
ondary antibodies for ELISA are listed in Supplementary Table 7. For IL-6 and IL-
9, ELISA kits (BioLegend) were used.
Chromatin immunoprecipitation. In vitro-differentiated Th cells were crosslinked
for 15 min with 1% formaldehyde at RT with rotation. The reaction was quenched
by adding 0.125M glycine and incubated at RT for 5 min. Fixed cells were lysed
with cell lysis buffer, followed by nuclear lysis buffer. Nuclei were degraded and
chromosomal DNA were fragmented to a size range of 200–500 bp through
ultrasonic processor (Vibra-cell). After sonication, the supernatant was diluted 10
fold with ChIP dilution buffer. After pre-clearing, the supernatant was incubated
with the ChIP antibodies at 4 °C overnight with rotation. The following day,
immunocomplexes were precipitated with Protein Agarose A or G beads at 4 °C for
2–4 h. Immunocomplexes were washed with low salt, high salt, LiCl and two times
with TE buffer. After elution followed by reverse crosslinks, DNA was puriﬁed and
analyzed by qPCR. After normalization to the Input DNA, the amount of output
DNA of each target protein was calculated by subtracting that of the IgG control.
ChIP antibodies and primer sequences are listed in Supplementary Table 8 and 9.
Chromosome conformation capture assay. In vitro-differentiated Th cells were
crosslinked for 15 min with 1% formaldehyde at RT with rotation. The reaction
was quenched by adding 0.125 M glycine and incubated at RT for 5 min. Fixed cells
were lysed with ice-cold cell lysis buffer 10 mM Tris-HCl [pH 8], 10 mM NaCl,
0.2% NP-40, and protease inhibitor mixture). Nuclei were incubated with restric-
tion enzyme buffer (NEB2) containing 0.3% SDS for 1 h while shaking at 900 rpm
at 37 °C. After adding 2% Triton X-100, nuclei were incubated another 1 h. DNA
was digested by adding 400 U Nco1 for overnight at 37 °C. Digestion was quenched
by adding 1.6% SDS for 25 min while shaking 900 rpm at 65 °C. After incubation of
digested nuclei with T4 DNA ligase buffer containing 1% Triton X-100 for 25 min
while shaking 900 rpm, DNA was ligated by adding 100 U T4 DNA ligase and
incubated for 4 h at 16 °C followed by cooling to RT. DNA was reverse-crosslinked
by adding proteinase K (10 mgml−1) and incubated for overnight at 65 °C. After
incubation of DNA with RNase (10 mgml−1) for 45 min at 37 °C, DNA was
puriﬁed and analyzed by qPCR. BAC clone (RP24-366P8) covering Il9 locus was
digested and ligated for reference standard curve of 3C qPCR. Interaction fre-
quencies were normalized to internal control.
Luciferase reporter assay. EL4 cells (2 × 106 cells) or primary cultured T cells
(5 × 106 cells) were co-transfected with 5 μg of the Il9 gene locus containing pGL3
basic vector and 5 μg control or IRF4 expressing pcDNA3.1 vector and 0.5 μg of
pRL-TK for endogenous control using Amaxa Nucleofection Kit L (Lonza). After
24 h of transfection, cells were stimulated with PMA/ionomycin for 6 h and luci-
ferase activities were measured using the dual luciferase reporter assay system
(Promega) according to the manufacturer’s instructions. Fireﬂy values were nor-
malized to renilla values; Fireﬂy values from luciferase reporter vectors, renilla
values from pRL-TK.
Chromatin accessibility assay. Chromatin was isolated from in vitro-cultured
T cells and digested with nuclease (Nse) mix using the EpiQuik chromatin
accessibility assay kit (Epigentek). Isolated chromatin was divided into two, one for
nuclease treatment, and another for non-treatment. After incubation at 37 °C for 4
min, reaction was quenched by adding reaction stop solution. DNA was puriﬁed
followed by qPCR to amplify DNA fragment with primers for CNS-25 (same as
ChIP primers) and Il9p or Hbb-bs for negative control (F: 5′-gagtggca-
cagcatccagggagaaa-3′, R: 5′-ccacaggccagagacagcagccttc-3′) The fold enrichment
(FE) was calculated by the formula: FE= 2^(Nse CT− no Nse CT) × 100%.
ChIP-seq analysis. ChIP was performed as described above and high-throughput
sequencing was performed by Array Star (Rockville, MD). Datasets are deposited in
Gene Expression Omnibus (GEO; GSE106404). Raw ChIP-Sequence reads (repli-
cates of p300 and Input (as control)) extracted from mouse Th9 cells in FASTQ
formats. We examined the quality of these paired end ChIP-Seq datasets using the
FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html) and ensured
the quality of sequence reads to a minimum quality score of 20 for each sample. We
used HISAT (with default parameters)64 for aligning the quality ﬁltered sequence
reads against mouse reference genome mm10. The aligned sequence data were
collected in SAM (Sequence Alignment/Map) ﬁles obtained as outputs from
HISAT. We employed MACS (version 1.4.2 201203052)65, an efﬁcient peak calling
algorithm, with default parameters for the identiﬁcation of p300 speciﬁc peaks
genome-wide in aligned p300 and Input ChIP-seq samples (merged for corre-
sponding replicates). Genomic distribution of p300-binding sites was analyzed by
Pavis (https://manticore.niehs.nih.gov/pavis2/)66 with the mm10 genomic anno-
tation. In this annotation analysis we have considered 50 kb upstream and 10 kb
downstream of peak sites to link all the p300-targeted genes where it could be
potentially acting as cis and or distant regulatory element. Published ChIP-seq
datasets (GSE22104 and GSE40463)33,34 were analyzed and graphed in the same
approach. DNA-binding motifs were identiﬁed using JASPAR and by hand with
published consensus sequences. ChIP-seq datasets are deposited in GEO
(GSE106404).
Th9-enriched gene list. RNA-seq results from Th9 cells (GSM1014577 and
GSM978775)22,67 were compared with RNA-seq data from other in vitro-derived
Th subsets (2-week data from GSE48138)68. FASTQ ﬁles were aligned to reference
ﬁle (mm9) and UCSC GTF ﬁle using tophat2 (tophat-2.0.13, parameter: no-novel-
juncs [Quantiﬁcation of reference annotation only]). FPKM values for each sample
were calculated using Cufﬂinks (cufﬂinks-2.2.1, default). Cuffnorm (cufﬂinks-2.2.1,
default settings) was used to combine and normalize FPKM values of each dataset.
The unique high expression genes of each dataset were selected by looking at a 16×
difference in expression and clustering analysis was performed on these selected
lists using R’s Pearson correlation.
Statistical analysis. Unless otherwise indicated, two-tailed Student’s t test or one-
way analysis of variance was used to generate p-value data for all data. Post hoc
Tukey test was used for multiple comparisons. p ≤ 0.05 was considered statistically
signiﬁcant.
Data availability
ChIP-seq datasets are deposited in GEO (GSE106404). All other data are available
upon communication with the authors. A reporting summary for this Article is
available as a Supplementary Information ﬁle.
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